BioCare Copenhagen is a Danish bioscience company that specializes in microbial actives targeting gastrointestinal disorders, metabolism, infections and immunity.
The company’s activities are based on research conducted at the Copenhagen University Hospital, Denmark’s leading hospital for patients requiring highly specialized treatment. BioCare Copenhagen was established as a joint venture between the Danish Ministry of Science, Technology and Innovation and the management team Søren B. Thomsen (CEO) and Jesper Gantzel (COO).
Biocare Copenhagen was acquired by Royal DSM in December 2017.
DSM is a global science-based company active in health, nutrition and materials. The company and its associated companies deliver annual net sales of about € 10 billion with approximately 25.000 employees and is listed at the Amsterdam Stock Exchange (Euronext NYSE) with a market capitalization of currently over EUR 12 billion.
DSM is a continuous leader in the Dow Jones Sustainability Index and the company have just been awarded the #2 position in Fortune’s “Change the World List”.